OBJECTIVES: Acromegaly, a relatively rare chronic endocrine disorder, results from excessive growth hormone (GH) secretion from a pituitary adenoma. Information on treatment practices and burden of acromegaly is limited. This study focused on assessing the burden of disease based on data retrieved from a large series of these patients. METHODS: A retrospective chart audit was conducted in September 2012 in US, France Italy and Brazil. Ninety-seven endocrinologists completed structured case report forms for the 4 most recentlyseen acromegaly patients (N=380); those on the last choice of medical therapy ≥6 months 'qualified' for this this analysis (N=335). Patient demographics, comorbidities, treatment history, insulin-like growth factor [IGF-1], random growth hormone [GH]), symptoms and health care resource utilization were recorded. Control of IGF-1 was defined as IGF-1≤1ULN, control of GH as GH≤2.5 μg/L. RESULTS: Fifty-two percent of patients were males, mean age 51 years; 63% with controlled IGF-1; 34% with controlled IGF-1+GH. The prevalence of comorbidities (hypertension, diabetes, arthritis) was similar in patients with controlled versus uncontrolled IGF-1 and in patients with controlled versus uncontrolled IGF-1+GH. The rate of paresthesia was significantly lower in patients with controlled versus uncontrolled IGF-1 (10% vs. 23%, p=0.003) and in patients with controlled versus uncontrolled IGF-1+GH (9% vs. 25%, p=0.015). Utilization of health care resources was similar in patients with controlled versus uncontrolled IGF-1 except for days hospitalized, which were significantly higher for patients with uncontrolled IGF-1 (p<0.05). Patients with controlled IGF-1+GH had significantly lower number of HCP visits, hospitalizations and length of hospitalization than those uncontrolled (p<0.01). In multivariable models predicting resource utilization based on biochemical control and comorbidities, IGF-1+GH control remained a statistically significant predictor of HCP visits, hospitalizations, and days hospitalized (p<0.05). CONCLUSIONS: This retrospective chart audit demonstrated that acromegaly patients with controlled IGF-1+GH have reduced symptom burden and resource utilization than uncontrolled patients.
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PATIENT-REPORTED FREQUENCY AND IMPACT OF HYPOGLYCEMIA IN TYPE-2 DIABETES PATIENTS RECEIVING PREMIXED INSULIN IN SEVEN EUROPEAN COUNTRIES
OBJECTIVES:
Hypoglycaemia is a common complication of insulin therapy and can impede optimal diabetes management, with implications for patients and health care resourcing. Many patients with Type-2 diabetes mellitus (T2DM) use premixed insulin regimens, but data on frequency and impact of hypoglycaemia in these patients are limited outside clinical trials. METHODS: A total of 3827 insulin-treated patients in Austria, Denmark, Finland, Norway, Netherlands, Sweden and Switzerland were recruited, mainly via online panels, to complete four questionnaires at week-intervals. Data were collected on demographics and non-severe hypoglycaemic events (NSHE) in the preceding seven days. NSHE was an event with symptoms of hypoglycaemia, with or without blood glucose measurement (BGM), or low BGM (≤55 mg/dl) without symptoms, which the patient managed without assistance. Severe hypoglycaemic events (SHE)defined as events requiring third-party assistance -were also reported. RESULTS: The 258 T2DM patients on premixed insulin reported 826 patientweeks. Mean insulin-treatment duration was 7 years, mean HbA1c7.9% (SD 1.6). Mean self-reported NSHEs were 0.52 per patient-week (SD 1.15), 33% of which were nocturnal (versus 23% in overall study). Mean annual frequency of SHEs was 0.2. Impaired awareness or unawareness of hypoglycaemia (answering 'usually/sometimes/never' to question 'can you feel when your blood sugar is low?') was reported in 57% (versus 63% in overall study). Of the 36% employed, 5% reported lost work time due to the last NSHE. Mean increase in BG test-strips was 3.2 over the 7 days following each NSHE. Nine percent of patients contacted a health care professional following a daytime, 10% following nocturnal NSHE. CONCLUSIONS: NSHE are common amongst premixed-insulin-treated T2DM patients; a third occurring at nighttime. NSHE were associated with work time loss and increased health care resource use, however hypoglycaemia awareness was low, and events not often reported to patients' GP/specialist. The real-world rates -and burden -of hypoglycaemia may therefore be underestimated.
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SELF-MONITORING BLOOD GLUCOSE: STRIPS CONSUMPTION RATE AND COSTS IN ARGENTINA
Elgart JF, Gonzalez L, Rucci E, Gagliardino JJ CENEXA -Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro Colaborador OPS/OMS), La Plata, Buenos Aires, Argentina BACKGROUND: Self-monitoring blood glucose (SMBG) is a useful tool to optimize diabetes control but increases its care cost. However, there is no data about its usage and cost in Argentina. OBJECTIVES: To estimate, in Argentina, the number of strips used for SMBG at the Social Security system (SSS) and its relationship with the type of treatment and degree of metabolic control. METHODS: An observational-retrospective study employing registries from the Pharmaceutical College of the Province of Buenos Aires (COLFARMA, 8115 anonymized recipes of drugs and strips prescribed in the period February to April 2012) and from one organization of the SSS (OSPERYH, 681 affiliates, strips consumption plus laboratory data during 2010). Statistical analysis includes ANOVA, t-test, U de Mann-Whitney and Kruskall-Wallis. RESULTS: OSPERYH: strips were provided under an audit system that assesses diabetes education, type of treatment and degree of metabolic control. Monthly overall average consumption was 24.6±14.5 (mean±SD) and it was strongly related to the treatment: insulin 34.5±16.6 and oral antidiabetic drugs (OAD) 22.5±12.6. In each group, people with HbA1c values < 7% consumed more strips than those above such value. COLFARMA: the overall average strips consumption was 97.5±70.1. The types of treatment significantly affect strips consumption: insulin alone 111.0±76.3, insulin+OAD 89.0±62.5, combined OAD 74.7±47.3 and OAD monotherapy 66.2±45.0 strips. Despite this consumption was almost four times larger than in OSPERYH, the treatmentdependent consumption pattern was similar in both groups. The strips represent, on average, 44 and 66% of the total cost of the prescription in COLFARMA and OSPERHY, respectively; and vary according to the treatment (OSPERHY and COLFARMA): OAD monotherapy 66 and 85%; combined OAD 39% and 62%; insulin 28 and 53%, respectively. CONCLUSIONS: The number of strips increased as a function of the type of treatment and attainment of therapeutic goals. Prescription audit significantly decreased such consumption. 
DIABETES/ENDOCRINE DISORDERS -Patient-Reported Outcomes & Patient Preference Studies PDB64 A SYSTEMATIC LITERATURE REVIEW OF METHODOLOGIES USED TO ASSESS MEDICATION ADHERENCE IN PATIENTS WITH DIABETES
OBJECTIVES:
Adhering to prescribed medication can be problematic for patients with diabetes yet there is no gold standard for measuring adherence in this patient population. This systematic literature review aimed to critically review and summarize the methods used to measure medication adherence in patients with diabetes in original research published between 2007-2012, and to highlight novel methods that are particularly relevant in assessing adherence to variabledosed insulin regimens. METHODS: A systematic search for articles describing methods to assess medication adherence in patients with type I or type II diabetes (on oral hypoglycemic agents, and/or insulin) was conducted using PubMed, EMBASE, PsychInfo, and Cochrane Databases. Two researchers independently screened abstracts for initial eligibility, then applied the inclusion/exclusion criteria to the relevant full-text articles. RESULTS: Fifty-five articles met the criteria for inclusion. In prospective studies, the identified medication adherence evaluation methods included subjective assessment (observer-reported and patient-reported), pill counts, Medication Event Monitoring System (MEMS), cell-phone real-time assessment and logbooks. Biochemical measurement as a proxy for adherence was also employed in some prospective studies. In all pharmacy claims database studies, medication possession ratios (MPRs), or some derivation thereof was utilized. Few approaches specifically addressed issues unique to assessing insulin adherence. However, two novel approaches (using cell-phone real-time assessment, and computerized logbooks) provided insight as to timing and dosing issues that could be useful for highlighting interventions to improve insulin adherence. CONCLUSIONS: No gold standard exists for measuring medication adherence in patients with diabetes. The plethora of adherence evaluation methods and different approaches to defining adherence/non-adherence precludes the comparison of adherence rates across studies. Greater consistency is therefore needed in adherence measurement, including question content, recall period, and response options for self-report measures, and definitions of "good adherence" for MPR. Novel methods for understanding adherence to variabledosed insulin require further research.
PDB65 ADHERENCE TO THERAPY AMONG DIABETES PATIENTS IN A NIGER DELTA REFERRAL CENTER
Suleiman IA, Siasia WO, Egbesu IE Niger Delta University, Wilberforce Island, Nigeria OBJECTIVES: Information on adherence among diabetes patient is rare in Bayelsa State, Niger Delta. The objective of the study was to determine the rate of adherence to therapy among diabetes mellitus patients. METHODS: It was a cross sectional survey with the use of an interviewer-administered questionnaire. A 4-item Morisky self-reported adherence scale in addition to other self-developed, validated and pretested questionnaires were used. This was administered to 263 patients receiving treatment at the Outpatient Department of the hospital after seeking and obtaining their consent between June and August 2012 on clinic days. Questions related to demographics, medication history, adherence rate, etc., were included. In addition, the respective case notes (263) of the same set of patients were examined, and relevant data extracted (such as blood glucose level). Data was appropriately analysed using SPSS. Descriptive statistics were used in presentation of results. RESULTS: Majority of the 210 patients (80.0%) were taking both metformin and glibenclamide tablets. About 60 percent, 156 (59.3%), of patients were adjudged adherent with prescribed medications on the 4-item Morisky scale of adherence with a score of 1.22±0.2, which differs significantly from the non-adherent group with a score of 3.34±0.87. (p<0.0001). However, overall adherences to all aspects of diabetes management were poorer as only 80 (30.5%) had normal fasting blood glucose level of less than 6.1mmol/l after at least five visits to the hospital. Only
